Member Info for Brand

From the CNN article/Pfizer press release:

"It said 19% of patients given the treatment suffered adverse events, compared to 21% who got placebo, but declined to disclose what those adverse events were.'

I would much rather be best, than first.

https://www.cnn.com/2021/11/05/health/pfizer-covid-antiviral-pill/index.html

Nice one Matml - thanks for that. This board is so good when it's not overrun with s***posters.

GLA

Matmi - It's a really good point to make. Fair play.

Indulging in a bit of 'reading between the lines' tho: knowing snr Mgmt has seen some data and there is enough of a signal on sprinter + RMs bullish mood in interviews + A2P3 + Activ manufacturing requirement met + nomination to pharma awards + new hires + 15 years of safety data....

Well - it's pretty damn good, innit. :)

This is massive tbf.

There's of course all sorts of genuine (and less genuine) bods on here that will throw all sorts at this, but I do think the best answer is no one knows.

We could wake up tomorrow morning to interim P3 results and an EUA and go to the moon, or drift for a few weeks until an in vitro RNS that barely gets a blip. At this point I think if you are genuinely in sng then you've gotta be in for the long haul not speculation.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217803

Reading through this study all I can think of is Phillip Morris' stated interest in pivoting to lung health. I know it's distasteful to most but they certainly have deep pockets and in an ideal T/O situ could really drive the price up.

Nah. Doc speaking mentions Dr Castro was working on an inhaled treatment, not a vaccine.

Curious if we're gonna get a big old jump in the last 15min.

Thanks All - it seems a really important point. Given case numbers in the US and the full weight of the US govt they should be able to fill this trial very quickly.

I have a question re A2P3 as I'm sure I've seen conflicting data on here.

To the best of my knowledge there is no placebo on P3? So when a patient is proposed to join a trial by ACTIV, they won't have to make a choice that is 50/50 drug vs placebo. This should certainly make recruitment easier and faster imo.

Doubled down on Monday. Brought my avg up to 171 bit when you're shooting for the stars what's a few pence...

BioNtech share prices:

June 2020 - 50USD
Dec 2020 -100USD
Aug 2021 - 371USD

Hold hold hold.

(Imho)

From my POV a JV w a major pharma is the most likely scenario. As there is the short term aspect of covid where production needs to be scaled quickly but the long term COPD/respatory/stockpiling and why would RM and the board give that up if they've got a silver bullet?

That was pre covid tho wasn't it? The you tube vid someone posted here a few days back of an investors forum had him quoting 8b USD

So if that's COPD, what's home AND hospital covid worth? The Merck mcap is up by about 8b on the back of the unapproved Ridgeback pill and that's only for early use.

1430 (gmt) kick off on SYGFF I believe

Genuine q for the more knowledgeable on this board.

Based on what we've seen w the merck drug, others what do you reckon each of these is worth

Home covid market
Hospital covid market
Stockpiling
COPD/general respiratory

I expect it's a heck of a lot, but would love to hear opinions

Don't look now but the SP is headed back up :)

You made me tap the sign.

Had a scrounge behind the couch and plowed every last penny in.